Search

CN-121975686-A - Use of Paralopecias Dirichardson and/or Paralopecias Jinshi in preparation of immunopotentiator of vaccine

CN121975686ACN 121975686 ACN121975686 ACN 121975686ACN-121975686-A

Abstract

The application relates to the technical field of immunity, and discloses a parabacteroides dirachta (Parabacteroides distasonis) and a parabacteroides aureoides (Parabacteroides goldsteinii), application of the parabacteroides dirachta and/or the parabacteroides aureoides in preparing an immunopotentiator of a vaccine, and an immunopotentiator of the vaccine. The Paralopecias parapsilosis and/or Paralopecias aurea can be used as an immunopotentiator, can activate immunity, enhance antibody titer, shorten antibody generation reaction time, and can remarkably promote proliferation of B cells, plasma cells and memory B cell subsets in germinal centers.

Inventors

  • ZHAO AI
  • Yang Celi
  • XI MENGLU

Assignees

  • 清华大学

Dates

Publication Date
20260505
Application Date
20260129

Claims (10)

  1. 1. A Paralopecuroides dirachta (Parabacteroides distasonis) is preserved in China general microbiological culture collection center with a preservation number of CGMCC No.35213.
  2. 2. A Paralopecuroides aurei (Parabacteroides goldsteinii) is preserved in China general microbiological culture collection center with a preservation number of CGMCC No.35214.
  3. 3. Use of parabacteroides dirachta (Parabacteroides distasonis) according to claim 1 and/or of parabacteroides aureoides (Parabacteroides goldsteinii) according to claim 2 in the preparation of an immunopotentiator for a vaccine.
  4. 4. The use according to claim 3, wherein the Paramycolatopsis Diels (Parabacteroides distasonis) and/or Paramycolatopsis Jinsii (Parabacteroides goldsteinii) enhance the potency of the antibodies after vaccination and/or shorten the vaccine response time, and/or Wherein the parabacteroides dirachta (Parabacteroides distasonis) and/or parabacteroides aureoides (Parabacteroides goldsteinii) are administered such that the cell proportion of germinal center B cells, plasma cells, and/or memory B cells of the vaccinated subject is increased.
  5. 5. The use of claim 3 or 4, wherein the parabacteroides diradii (Parabacteroides distasonis) and/or parabacteroides aureoides (Parabacteroides goldsteinii) are administered before, after or simultaneously with vaccination.
  6. 6. The use according to any one of claims 3-5, wherein the vaccine is an inactivated vaccine, an attenuated live vaccine, a protein vaccine, a DNA vaccine or a polypeptide vaccine; Preferably, the vaccine is selected from any one or more of rabies vaccine, influenza vaccine, pneumonia vaccine, hepatitis B vaccine, hepatitis A vaccine, hepatitis C vaccine, hand-foot-and-mouth vaccine and HPV vaccine.
  7. 7. An immunopotentiator for a vaccine comprising the parabacteroides diradii (Parabacteroides distasonis) of claim 1 and/or the parabacteroides aureoides (Parabacteroides goldsteinii) of claim 2.
  8. 8. The immunopotentiator of claim 7, wherein the immunopotentiator enhances the potency of the antibody after vaccination and/or shortens the vaccine response time, and/or Wherein the immunopotentiator is administered such that the cell proportion of germinal center B cells, plasma cells, and/or memory B cells of the vaccinated subject is increased, and/or Wherein the immunopotentiator is administered before, after or simultaneously with vaccination.
  9. 9. The immunopotentiator of claim 7 or 8, wherein the vaccine is an inactivated vaccine, an attenuated live vaccine, a protein vaccine, a DNA vaccine, or a polypeptide vaccine; Preferably, the vaccine is selected from any one or more of the group consisting of rabies vaccine, influenza vaccine, hepatitis B vaccine, hepatitis A vaccine, hepatitis C vaccine, hand-foot-and-mouth vaccine and HPV vaccine.
  10. 10. The immunopotentiator of any one of claims 7-9, wherein the immunopotentiator further comprises a pharmaceutically acceptable carrier.

Description

Use of Paralopecias Dirichardson and/or Paralopecias Jinshi in preparation of immunopotentiator of vaccine Technical Field The application belongs to the technical field of immunization, and particularly relates to application of parabacteroides dirachta and/or parabacteroides aureoides in preparing an immunopotentiator of a vaccine and the immunopotentiator of the vaccine. Background The intestinal bacteria are important components of human intestinal microorganisms, and have important regulation effects on metabolism, cognition and immunity of human bodies. The Paramycolatopsis (Parabacteroides) is a core member of the human intestinal microbiota, and the detection rate in the human intestinal sample database is more than 90%. Paralopecias dieldrin (Parabacteroides distasonis, P. Distasonis) and Paralopecias aurea (Parabacteroides goldsteinii, P. Goldsteinii) are two species under the genus Paralopecias, both gram negative. Researches show that the Chinese medicinal composition has a protective effect on diseases such as obesity, non-alcoholic fatty liver disease, diabetes and the like. The immune response is a series of biological activities such as activation, proliferation, differentiation and effector molecule generation of immune cells after the immune system of the organism recognizes antigen stimulation. The level of immune response following host vaccination directly affects the effectiveness of the immunization. The existing vaccine system still has the limitation of insufficient immunogenicity, in particular to the traditional vaccine platforms such as inactivated vaccines, and the immune response efficiency is low due to the factors such as insufficient presentation of antigen epitopes, limited immune activation intensity and the like. The problem is particularly prominent in the special groups such as the old population, the immunocompromised individuals and the like, is manifested by insufficient antibody titer, imperfect immunological memory formation, reduced protective effect and the like, and severely restricts the prevention effect and the application value of the vaccine. Therefore, the vaccine immune response is safely and efficiently promoted, and the research and development of the vaccine immunopotentiator can effectively protect fragile people and block disease development. Disclosure of Invention In order to solve the problems in the prior art, the application provides parabacteroides dirachta and/or parabacteroides aureoides, application thereof in preparing immunopotentiator of vaccine and immunopotentiator of vaccine. In particular, the application relates to the following aspects: 1. A Paralopecuroides dirachta (Parabacteroides distasonis) is preserved in China general microbiological culture collection center with a preservation number of CGMCC No.35213. 2. A Paralopecuroides aurei (Parabacteroides goldsteinii) is preserved in China general microbiological culture collection center with a preservation number of CGMCC No.35214. 3. The use of the parabacteroides dirachta (Parabacteroides distasonis) described in item 1 and/or the parabacteroides aureoides (Parabacteroides goldsteinii) described in item 2 in the preparation of an immunopotentiator of a vaccine. 4. The use according to item 3, wherein the Paralopecuroides dirachta (Parabacteroides distasonis) and/or Paralopecuroides aureobasidium (Parabacteroides goldsteinii) enhance the potency of the antibody after vaccination and/or shorten the vaccine response time, and/or Wherein the parabacteroides dirachta (Parabacteroides distasonis) and/or parabacteroides aureoides (Parabacteroides goldsteinii) are administered such that the cell proportion of germinal center B cells, plasma cells, and/or memory B cells of the vaccinated subject is increased. 5. The use of item 3 or 4, wherein the parabacteroides dirachta (Parabacteroides distasonis) and/or parabacteroides aureoides (Parabacteroides goldsteinii) are administered before, after or simultaneously with the vaccination. 6. The use of any one of claims 3-5, wherein the vaccine is an inactivated vaccine, an attenuated live vaccine, a protein vaccine, a DNA vaccine, or a polypeptide vaccine; Preferably, the vaccine is selected from any one or more of rabies vaccine, influenza vaccine, pneumonia vaccine, hepatitis B vaccine, hepatitis A vaccine, hepatitis C vaccine, hand-foot-and-mouth vaccine and HPV vaccine. 7. An immunopotentiator for a vaccine, comprising the parabacteroides diradii (Parabacteroides distasonis) of item 1 and/or the parabacteroides aureoides (Parabacteroides goldsteinii) of item 2. 8. The immunopotentiator of item 7, wherein the immunopotentiator enhances the potency of an antibody after vaccination and/or shortens the vaccine response time, and/or Wherein the immunopotentiator is administered such that the cell proportion of germinal center B cells, plasma cells, and/or memory B cells of the vaccinated subject is increased, and/or Wherein the immunopotentiato